» Articles » PMID: 20951943

Nuclear Cyclin D1/CDK4 Kinase Regulates CUL4 Expression and Triggers Neoplastic Growth Via Activation of the PRMT5 Methyltransferase

Overview
Journal Cancer Cell
Publisher Cell Press
Specialty Oncology
Date 2010 Oct 19
PMID 20951943
Citations 135
Authors
Affiliations
Soon will be listed here.
Abstract

Cyclin D1 elicits transcriptional effects through inactivation of the retinoblastoma protein and direct association with transcriptional regulators. The current work reveals a molecular relationship between cyclin D1/CDK4 kinase and protein arginine methyltransferase 5 (PRMT5), an enzyme associated with histone methylation and transcriptional repression. Primary tumors of a mouse lymphoma model exhibit increased PRMT5 methyltransferase activity and histone arginine methylation. Analyses demonstrate that MEP50, a PRMT5 coregulatory factor, is a CDK4 substrate, and phosphorylation increases PRMT5/MEP50 activity. Increased PRMT5 activity mediates key events associated with cyclin D1-dependent neoplastic growth, including CUL4 repression, CDT1 overexpression, and DNA rereplication. Importantly, human cancers harboring mutations in Fbx4, the cyclin D1 E3 ligase, exhibit nuclear cyclin D1 accumulation and increased PRMT5 activity.

Citing Articles

Transcription coactivator YAP1 promotes CCND1/CDK6 expression, stimulating cell proliferation in cloned cattle placentas.

Wu S, Zhao X, Yang L, Hai C, Wu D, Liu X Zool Res. 2025; 46(1):122-138.

PMID: 39846191 PMC: 11890997. DOI: 10.24272/j.issn.2095-8137.2024.211.


Cyclin-dependent protein kinases and cell cycle regulation in biology and disease.

Pellarin I, DallAcqua A, Favero A, Segatto I, Rossi V, Crestan N Signal Transduct Target Ther. 2025; 10(1):11.

PMID: 39800748 PMC: 11734941. DOI: 10.1038/s41392-024-02080-z.


PRKD3 promotes proliferation of liver cancer cells: a downstream proteomics profiling study.

Tian Y, Xie B, Wang S, Ma X, Deng H, Ma L Am J Transl Res. 2024; 16(11):6384-6398.

PMID: 39678603 PMC: 11645616. DOI: 10.62347/YLJE5332.


Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer.

Guo Y, Li Y, Zhou Z, Hou L, Liu W, Ren W J Exp Clin Cancer Res. 2024; 43(1):314.

PMID: 39614393 PMC: 11607928. DOI: 10.1186/s13046-024-03237-y.


Emerging Targets in Non-Small Cell Lung Cancer.

Liu L, Soler J, Reckamp K, Sankar K Int J Mol Sci. 2024; 25(18).

PMID: 39337530 PMC: 11432526. DOI: 10.3390/ijms251810046.


References
1.
Pal S, Vishwanath S, Erdjument-Bromage H, Tempst P, Sif S . Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol. 2004; 24(21):9630-45. PMC: 522266. DOI: 10.1128/MCB.24.21.9630-9645.2004. View

2.
Liu F, Matsuura I . Inhibition of Smad antiproliferative function by CDK phosphorylation. Cell Cycle. 2004; 4(1):63-6. DOI: 10.4161/cc.4.1.1366. View

3.
Bani-Hani K, Martin I, Hardie L, Mapstone N, Briggs J, Forman D . Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst. 2000; 92(16):1316-21. DOI: 10.1093/jnci/92.16.1316. View

4.
Bartkova J, Lukas J, Strauss M, Bartek J . The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int J Cancer. 1994; 58(4):568-73. DOI: 10.1002/ijc.2910580420. View

5.
Aggarwal P, Lessie M, Lin D, Pontano L, Gladden A, Nuskey B . Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. Genes Dev. 2007; 21(22):2908-22. PMC: 2049193. DOI: 10.1101/gad.1586007. View